SPH Stock Overview Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Sopharma AD Historical stock prices Current Share Price лв12.25 52 Week High лв16.10 52 Week Low лв11.40 Beta -0.026 1 Month Change -12.19% 3 Month Change -7.20% 1 Year Change -13.43% 3 Year Change 18.93% 5 Year Change 26.81% Change since IPO 63.33%
Recent News & Updates Sopharma AD to Report Fiscal Year 2025 Final Results on Apr 30, 2026 Sopharma AD to Report Q1, 2025 Results on May 30, 2025
Third quarter 2024 earnings released: EPS: лв0.11 (vs лв0.12 in 3Q 2023) Dec 01
Upcoming dividend of лв0.075 per share Nov 01
Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023) Sep 01
New minor risk - Share price stability Aug 09 See more updates Sopharma AD to Report Fiscal Year 2025 Final Results on Apr 30, 2026 Sopharma AD to Report Q1, 2025 Results on May 30, 2025
Third quarter 2024 earnings released: EPS: лв0.11 (vs лв0.12 in 3Q 2023) Dec 01
Upcoming dividend of лв0.075 per share Nov 01
Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023) Sep 01
New minor risk - Share price stability Aug 09
Independent Director recently bought zł728k worth of stock Jun 26
Chairman recently bought zł82k worth of stock Jun 08
First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023) Jun 04
Full year 2023 earnings released: EPS: лв0.73 (vs лв0.58 in FY 2022) Mar 03
New major risk - Revenue and earnings growth Jan 25
Investor sentiment improves as stock rises 22% Jan 09
Chairman recently sold zł131k worth of stock Dec 22 Sopharma AD, Annual General Meeting, Jun 30, 2024
Chairman recently bought zł749k worth of stock Dec 14
New major risk - Financial position Dec 08
Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022) Dec 01
Upcoming dividend of лв0.90 per share at 8.5% yield Nov 30
Now 30% undervalued Nov 29
Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024 Nov 25
Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023 Oct 31
Investor sentiment deteriorates as stock falls 15% Oct 26
Now 26% undervalued Oct 13
New minor risk - Shareholder dilution Oct 12
Investor sentiment improves as stock rises 19% Oct 05
Chairman recently bought zł170k worth of stock Oct 01
Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023 Sep 21
Chairman recently bought zł190k worth of stock Sep 13
Investor sentiment improves as stock rises 16% Sep 11
Chairman recently sold zł2.4m worth of stock Sep 07
Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia. Sep 06
Second quarter 2023 earnings released: EPS: лв0.26 (vs лв0.19 in 2Q 2022) Sep 02
New minor risk - Shareholder dilution Aug 31
Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o. Jul 16
Chairman recently sold zł673k worth of stock Jul 05
Investor sentiment deteriorates as stock falls 20% Jun 25
New minor risk - Dividend sustainability Jun 14
Investor sentiment improves as stock rises 26% Jun 10
Upcoming dividend of лв0.60 per share Jun 09
Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023 Jun 03
First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022) May 31
Less than half of directors are independent May 09
Full year 2022 earnings released: EPS: лв0.60 (vs лв0.71 in FY 2021) Mar 06
Investor sentiment improves as stock rises 17% Feb 27
Sopharma AD, Annual General Meeting, Jun 30, 2023 Dec 22 Sopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024
Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021) Dec 01
Less than half of directors are independent Nov 16
Now 20% undervalued after recent price drop Oct 24
Now 29% undervalued after recent price drop Oct 07
Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021) Aug 31
Now 27% undervalued Aug 18
Now 24% undervalued after recent price drop Jul 22
Now 21% undervalued Jul 04
Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million. Jun 09
First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021) Jun 02
Less than half of directors are independent May 31
Less than half of directors are independent May 05
Sopharma AD, Annual General Meeting, Jun 03, 2022 May 03
Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022 Apr 06
Investor sentiment improved over the past week Mar 14
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 03
Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 03
An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA). Dec 30
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Dec 02
Second quarter 2021 earnings released Sep 03
Chairman recently bought zł182k worth of stock Sep 03
Less than half of directors are independent Jul 27
First quarter 2021 earnings released Jun 03
Revenue beats expectations Mar 05
Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019) Mar 05
Investor sentiment improved over the past week Feb 03
Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ. Jan 10
Investor sentiment improved over the past week Jan 05
An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR). Dec 30
Investor sentiment improved over the past week Dec 28
New 90-day low: zł9.30 Dec 14
Market pulls back on stock over the past week Nov 26
New 90-day low: zł10.00 Nov 26
Market pulls back on stock over the past week Nov 02
Market bids up stock over the past week Oct 27
New 90-day low: zł11.80 Oct 21
Market pulls back on stock over the past week Oct 16
Market pulls back on stock over the past week Oct 13
New 90-day high - zł19.00 Aug 15 Shareholder Returns SPH PL Pharmaceuticals PL Market 7D -6.1% 0.6% -2.6% 1Y -13.4% 26.7% -4.9%
See full shareholder returns
Return vs Market: SPH underperformed the Polish Market which returned -4.9% over the past year.
Price Volatility Is SPH's price volatile compared to industry and market? SPH volatility SPH Average Weekly Movement 9.6% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.9% 10% most volatile stocks in PL Market 8.7% 10% least volatile stocks in PL Market 3.2%
Stable Share Price: SPH's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: SPH's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices, such as gauzes, compresses, and dressing.
Show more Sopharma AD Fundamentals Summary How do Sopharma AD's earnings and revenue compare to its market cap? SPH fundamental statistics Market cap zł2.12b Earnings (TTM ) zł178.42m Revenue (TTM ) zł4.48b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SPH income statement (TTM ) Revenue лв2.05b Cost of Revenue лв1.60b Gross Profit лв451.40m Other Expenses лв369.49m Earnings лв81.91m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
Earnings per share (EPS) 0.49 Gross Margin 21.97% Net Profit Margin 3.99% Debt/Equity Ratio 36.3%
How did SPH perform over the long term?
See historical performance and comparison Dividends
2.6% Current Dividend Yield When do you need to buy SPH by to receive an upcoming dividend? Sopharma AD dividend dates Ex Dividend Date Nov 07 2024 Dividend Pay Date Dec 23 2024 Days until Ex dividend 45 days Days until Dividend pay date 1 day
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 09:07 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sopharma AD is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mihail Dimitrov First Financial Brokerage House Bram Buring Wood & Company
Show 0 more analysts 
